Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track JBIO with free AI briefings, catalyst countdowns, and dilution alerts.

JBIO · Jade Biosciences, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$475.7M Cash on Hand
39.3mo Cash Runway
Follow JBIO by email Get an email when JBIO reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about JBIO, unsubscribe in one click. Privacy

📣 What JBIO Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
JADE101 IgA Nephropathy (IgAN) Phase 3 · NCT07902817 Recruiting
JADE201 Rhematoid Arthritis Phase 1 · NCT07533955 Recruiting

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

JBIO holds $475.7M in cash and short-term investments (as of Sep 30, 2026) and burns about $36.3M/quarter from operations, an estimated runway of 39.3 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 45 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when JBIO files for a raise →

👥 Who Owns JBIO

Insiders 21.3% Other 5%+ holders 14.3% Institutions (218 holders) 64.4% Public and other holders 0%
HolderTypeShares% of sharesAs of
Fairmount Funds Management LLC
Director, 10% owner · +912,907 options
Insider 14,069,494 20.33% 2026-06-05
JANUS HENDERSON GROUP Ltd. Institution (13G, 5%+) 6,273,262 9.07% 2026-06-30
Paradigm BioCapital Advisors LP 5%+ holder (13G) 6,053,268 8.75% 2026-09-30
Bellevue Group AG Institution (13G, 5%+) 4,293,937 6.21% 2026-09-30
Venrock Healthcare Capital Partners III, 5%+ holder (13G) 3,858,984 5.58% 2026-09-30
Franklin Templeton, Inc. Institution (13G, 5%+) 3,807,236 5.50% 2026-09-30
BlackRock, Inc. Institution (13G, 5%+) 3,323,301 4.80% 2026-09-30
Andrew James King
Chief Scientific Officer & Head of Resea · +247,500 options
Insider 386,113 0.56% 2026-02-12
Tom Frohlich
Chief Executive Officer, Director · +472,500 options
Insider 86,331 0.12% 2026-02-12
Lawrence Otto Klein
Director · +57,860 options
Insider 86,215 0.12% 2025-04-28
Bradford D. Dahms
Chief Financial Officer · +752,875 options
Insider 37,813 0.05% 2026-02-12
Elizabeth Balta
Chief Legal Officer and Corporate Secret · +168,750 options
Insider 28,125 0.04% 2026-02-12

Share count 69,189,448 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full JBIO picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for JBIO and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.